The NADINA trial, presented as a plenary abstract at the American Society of Clinical Oncology meeting, provides confirmation of the idea of using immunotherapy in the neoadjuvant setting in melanoma, but the combination of Bristol Myers Squibb Company’s Opdivo (nivolumab) and Yervoy (ipilimumab) may not be the regimen that ultimately moves forward.
There has been a move toward neoadjuvant treatment of melanoma with immunotherapy in recent years, with NADINA (sponsored by the Netherlands Cancer Institute) building on Phase II trials like the OpACIN-neo trial of Opdivo/Yervoy and the SWOG 1801 trial of competitor